Praluent Deal Combines Price Break With Point-Of Sale Rebates; Express Scripts Wants To Do More
Executive Summary
Express Scripts expects to develop similar coverage agreements, including point-of-sale rebates, with other manufacturers. Upcoming migraine drugs may be candidates.
You may also be interested in...
Let's Make A Deal: Sanofi/Regeneron Extend A Hand On Praluent, Express Scripts Takes It
Express Scripts has agreed to give Praluent preferred access over Amgen's Repatha on its national formulary and is removing restrictions that have been a significant barrier to market access for the PCSK9 inhibitors.
UnitedHealthcare Will Apply About 80% Of Rebates At Point-Of-Sale
Insurer offers additional details on upcoming rebate program, including how it will protect contract confidentiality, and which members might use it the most.
New Migraine Drugs May Not Be Cost Effective In Patients With Other Options, ICER Suggests
Draft cost effectiveness report released by the Institute for Clinical and Economic Review uses $8,500 annual cost for Aimovig and fremanezumab as a "placeholder" price.